Taken together, these results shed light on the interaction between liquiritigenin and the NRF2/SIRT3 pathway in CP-induced nephrotoxicity, suggesting that targeting mitochondrial function by liquiritigenin may provide unexpected opportunities for the treatment of CP-induced AKI patients. The gene discussed is NFE2L2; the disease is acute kidney injury.